KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Revenue (2016 - 2025)

Historic Revenue for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $187.8 million.

  • Neogenomics' Revenue rose 1190.12% to $187.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $709.2 million, marking a year-over-year increase of 1009.81%. This contributed to the annual value of $660.6 million for FY2024, which is 1164.94% up from last year.
  • Per Neogenomics' latest filing, its Revenue stood at $187.8 million for Q3 2025, which was up 1190.12% from $181.3 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Revenue ranged from a high of $187.8 million in Q3 2025 and a low of $115.5 million during Q1 2021
  • For the 5-year period, Neogenomics' Revenue averaged around $146.5 million, with its median value being $146.9 million (2023).
  • Examining YoY changes over the last 5 years, Neogenomics' Revenue showed a top increase of 3994.96% in 2021 and a maximum decrease of 327.16% in 2021.
  • Over the past 5 years, Neogenomics' Revenue (Quarter) stood at $125.7 million in 2021, then grew by 10.32% to $138.7 million in 2022, then increased by 12.15% to $155.6 million in 2023, then increased by 10.57% to $172.0 million in 2024, then grew by 9.18% to $187.8 million in 2025.
  • Its last three reported values are $187.8 million in Q3 2025, $181.3 million for Q2 2025, and $168.0 million during Q1 2025.